Updating results

3791 results

Sort: Relevance | Date

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic pain: oral ketamine (ESUOM27)

Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

Evidence summary Published February 2014 Last updated June 2014

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

Summary of the evidence on melatonin for sleep disorders in children and young people with attention deficit hyperactivity disorder (ADHD)..

Evidence summary Published January 2013

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

Evidence summary Published July 2013 Last updated September 2014

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

Summary of the evidence on fluticasone furoate plus vilanterol for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published June 2013

Type 2 diabetes: alogliptin (ESNM20)

Summary of the evidence on alogliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor) for type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published May 2013 Last updated October 2014

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

Summary of the evidence on lisdexamfetamine dimesylate for attention defecit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published May 2013

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

Summary of the evidence on tadalafil for lower urinary tract symptoms secondary to benign prostate hyperplasia..

Evidence summary Published May 2013 Last updated October 2013

Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

Summary of the evidence on zonisamide as monotherapy for children and young people with epilepsy to inform local NHS planning and decision-making

Evidence summary Published April 2013

Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

Summary of the evidence on linaclotide for irritable bowel syndrome (IBS) with constipation in adults to inform local NHS planning and decision-making

Evidence summary Published April 2013

Actinic keratosis: ingenol mebutate gel (ESNM14)

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

Summary of the evidence on racecadotril with oral rehydration for treating acute diarrhoea in children to inform local NHS planning and decision-making

Evidence summary Published March 2013

Acute diarrhoea in adults: racecadotril (ESNM11)

Summary of the evidence on racecadotril for treating acute diarrhoea in adults to inform local NHS planning and decision-making

Evidence summary Published March 2013

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published April 2015

Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Chronic obstructive pulmonary disease: olodaterol (ESNM54)

Summary of the evidence on olodaterol for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Erectile dysfunction: Alprostadil cream (ESNM50)

Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published December 2014

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

CentriMag for heart failure (MIB92)

Advice on the use of CentriMag for heart failure to aid local decision-making

Medtech innovation briefing Published January 2017

Boston Keratoprosthesis Type I for corneal blindness (MIB91)

Advice on the use of Boston Keratoprosthesis Type I for treating corneal blindness to aid local decision-making

Medtech innovation briefing Published January 2017

Antimicrobial prescribing: meropenem with vaborbactam (ES21)

Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

Evidence summary: antimicrobial prescribing Published November 2019

Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

Evidence summary: antimicrobial prescribing Published December 2019

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Renin-angiotensin system drugs: dual therapy (KTT2)

The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated February 2016